ArticleClinical and experimental gastroenterology2025
Chemopreventive Effects of Statins and Aspirin on Colorectal Cancer Among Patients with Inflammatory Bowel Disease: Evidence of a Synergistic Association from a Large Cohort.
Article in Clinical and experimental gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic role of statins in colorectal cancer: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Pharmacologic Modulation of the PAR-2-ERK Axis by Statins Converts Inflammatory Survival Signalling into Apoptosis in Colorectal Cancer Cells.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients with Inflammatory Bowel Disease (IBD) are at an increased risk of developing colorectal cancer (CRC). While numerous studies have explored chemoprevention strategies in the general population, the specific roles of statins and aspirin in reducing CRC risk among IBD patients remain inconclusive. Aim: This study aims to evaluate the effect of statins on CRC risk and investigates whether combining statins and aspirin further reduces CRC risk in this high-risk population. Methods: We included 11,325 IBD patients from the Northwell Health Information Exchange (HIE) database (2008-2023). Demographic and clinical variables were collected. The primary endpoint was CRC development, while the secondary endpoint was the occurrence of any cancer. Multivariable logistic regression assessed the association between cancer development and statin use, adjusted for confounders. Subgroup analyses evaluated the combined effect of statins and aspirin compared to non-users and aspirin-only users. Statistical significance was defined as a p-value <0.05. Results: Among 11,325 patients (mean age 65.1± 20.4 years, 54.5% females, 68% white), 2,809 (24.8%) used statins. Logistic regression analysis revealed that statin use was associated with lower odds of CRC, although it did not reach statistical significance (OR: 0.647, p = 0.0564). It was, however, significantly associated with a reduced risk of any cancer (OR: 0.630, p<0.0001). Furthermore, combining statins and aspirin significantly reduced the risk of CRC (OR: 0.163, p=0.0028) and any cancer (OR: 0.367, p<0.0001) compared to non-users. When compared to aspirin-only users, the statin-aspirin combination was associated with significantly lower odds of CRC (OR: 0.235, p=0.0289) and any cancer (OR: 0.522, p=0.0087). Conclusion: Statins are associated with a reduced risk of any cancer and a potential reduction in CRC in patients with IBD. The combination of statin-aspirin demonstrates a significant and synergistic protective effect, supporting its potential role in chemoprevention strategies for this high-risk population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.